Adicet Bio (ACET)

• Market cap: $58.6M
• 1 day: -5.56%
• 5 days: -7.28%
• 1 month: -16.19%
• 3 months: -22.95%
• 6 months: -52.85%
• Year to date: -30.73%
• 1 year: -49.42%
• 5 years: -97.07%
• 10 years: -99.68%
• Sector: Healthcare
• Industry: Biotechnology

About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Employees: 102